XFOR

X4 PHARMACEUTICALS, INC

XFOR · CIK 1501697 · Annual (10-K) · Last 7 years

Financial Trends

Revenue$3M
20182024
Net Income−$37M
20182024
Operating CF−$131M
20182024
Free Cash Flow−$131M
20182024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.0B—$0.0B$0.0B$0.0B—$0.0B
Cost of Revenue$0.0B——————
Gross Profit———————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
SG&A Expense———————
Operating Income$-0.0B$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Net Income$-0.0B$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-0.19$-0.57$-1.52————
EPS (Diluted)$-0.19$-0.57$-1.52————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.1B$0.1B$0.2B$0.1B$0.1B$0.2B$0.0B
Current Assets$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B
Cash & Equivalents$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B
Total Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B
Investing Cash Flow$0.1B$-0.0B$-0.0B$-0.0B$-0.0B$0.0B$-0.0B
Capital Expenditures$0.0B——————
Financing Cash Flow$0.0B$0.1B$0.1B$0.1B$0.0B$0.1B$-0.0B
← Companies